<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Despite its geographic proximity to the epicentre of the COVID-19 outbreak and the significant amount of travel transit, Taiwan has handled the outbreak exceptionally well [
 <xref rid="bib30" ref-type="bibr">30</xref>]. To date, the number of total cases amounts to only 481, with 7 deaths.
 <xref rid="fn6" ref-type="fn">6</xref> By the end of April, the outbreak was already nearly over in the country [
 <xref rid="bib31" ref-type="bibr">31</xref>]. A swift response by the government, a well-thought-out organisation of good quality medical facilities, contact tracing, and lessons learn from the 2003 SARS outbreak all contributed to the Taiwanese success, all of them being outlined in a series of short articles in this issue of the 
 <italic>Biomedical Journal</italic>. In addition to the spotless management of the crisis, the National Health Research Institute (NHRI) set up a biobank for COVID-19 blood samples in record time with the goal to help with the urgent need for diagnosis and treatment tools, and to provide research material for data mining in the long term. Huang etÂ al. describe the different features of the biobank project, including the facilities, legal framework, and standard operation procedures, as well as the possibilities provided by the available data [
 <xref rid="bib32" ref-type="bibr">32</xref>].
</p>
